Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience-Reference-Cited by-同舟云学术

Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience

Published:2020 Issue: Volume:24 Page:100188
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Battisti Nicolò Matteo Luca,Rogerson Frances,Lee Karla,Shepherd Scott,Mohammed Kabir,Turner Nicholas,McGrath Sophie,Okines Alicia,Parton Marina,Johnston Stephen,Allen Mark,Ring Alistair

Funder

NIHR

The Cridlan Ross Smith Charitable Trust

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference18 articles.

1. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer;Isakoff;J. Clin. Oncol.,2011

2. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial;Dieras;Lancet Oncol.,2017

3. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial;Krop;Lancet Oncol.,2014

4. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial;Krop;Lancet Oncol.,2017

5. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N. Engl. J. Med.,2012

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study;Journal of Chemotherapy;2024-06-21

2. Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-01-24

3. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer;The Breast;2022-12

4. Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study;Anti-Cancer Drugs;2022-11-19

5. Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer;Genes;2022-11-08